Puma Biotechnology (PBYI) News Today

HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday.

Puma Biotechnology (NASDAQ:PBYI) will be releasing earnings after the market closes on Thursday, August 1, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=610403)

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) CFO Maximo F. Nougues sold 5,295 shares of Puma Biotechnology stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $3.27, for a total transaction of $17,314.65. Following the completion of the sale, the chief financial officer now directly owns 166,678 shares of the company's stock, valued at approximately $545,037.06. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Puma Biotechnology (NASDAQ:PBYI) Stock Price Crosses Below Two Hundred Day Moving Average of $4.83

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Troy Edward Wilson sold 27,000 shares of the company's stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $3.33, for a total value of $89,910.00. Following the sale, the director now owns 350 shares in the company, valued at $1,165.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) was the recipient of a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 2,510,000 shares, a drop of 17.4% from the May 15th total of 3,040,000 shares. Based on an average daily volume of 413,900 shares, the days-to-cover ratio is currently 6.1 days. Approximately 7.1% of the shares of the company are short sold.

Great Point Partners LLC purchased a new stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,093,273 shares of the biopharmaceutical company

StockNews.com raised shares of Puma Biotechnology from a "hold" rating to a "buy" rating in a research note on Wednesday.

HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Puma Biotechnology in a research report on Monday.

StockNews.com upgraded shares of Puma Biotechnology from a "hold" rating to a "buy" rating in a report on Friday.

HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Friday.

StockNews.com lowered Puma Biotechnology from a "buy" rating to a "hold" rating in a report on Wednesday.

Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Equities researchers at Zacks Research cut their FY2025 earnings estimates for Puma Biotechnology in a research note issued to investors on Wednesday, April 3rd. Zacks Research analyst K. Shah now expects that the biopharmaceutical company wi

Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Analysts at Zacks Research decreased their Q1 2024 EPS estimates for shares of Puma Biotechnology in a research note issued to investors on Tuesday, March 19th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company

Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Analysts at Zacks Research issued their FY2026 earnings estimates for shares of Puma Biotechnology in a note issued to investors on Tuesday, March 19th. Zacks Research analyst K. Shah forecasts that the biopharmaceutical company will post ear

Puma Biotechnology (NASDAQ:PBYI) Stock Price Crosses Above Two Hundred Day Moving Average of $4.13